Skip to main content

Drug Interactions between Lamprene and voclosporin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

clofazimine voclosporin

Applies to: Lamprene (clofazimine) and voclosporin

Consumer information for this interaction is not currently available.

ADJUST DOSE: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of voclosporin, which is primarily metabolized by the isoenzyme. Elevated plasma concentrations of voclosporin may increase the risk for adverse effects such as acute and/or chronic nephrotoxicity, infection, hypertension, neurotoxicity, and QT prolongation. The risk of QT prolongation in particular may be increased with concomitant use of moderate CYP450 3A4 inhibitors that are also known to prolong the QT interval (e.g., crizotinib, dronedarone, erythromycin, fluconazole). Drug interaction studies have shown that coadministration with the moderate CYP450 3A4 inhibitor verapamil (80 mg three times daily for 10 days) increased the peak plasma concentration (Cmax) systemic exposure (AUC) by approximately 2- and 2.71-fold, respectively. Coadministration with a weak CYP450 3A4 inhibitor is not expected to have a clinically significant effect on voclosporin exposure.

MANAGEMENT: The manufacturer recommends a dose reduction of voclosporin to 15.8 mg in the morning and 7.9 mg in the evening when it is used concomitantly with moderate CYP450 inhibitors such as verapamil, diltiazem, and fluconazole. Patients should be monitored for adverse effects associated with voclosporin and advised to notify their doctor if they experience possible signs and symptoms of infection, nephrotoxicity, hypertension, neurotoxicity, and QT prolongation.

References

  1. (2021) "Product Information. Lupkynis (voclosporin)." Aurinia Pharma

Drug and food interactions

Major

voclosporin food

Applies to: voclosporin

Food may delay and reduce the absorption of voclosporin, which may lead to lower blood levels of the medication and possibly reduced effectiveness. Voclosporin should be taken on an empty stomach at least 1 hour before or 2 hours after food. This will make it easier for your body to absorb the medication. Also, while taking voclosporin, you should avoid grapefruits and grapefruit juice. Grapefruit can raise the blood levels of voclosporin in your body and lead to increased adverse effects. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor. Also, if you are taking voclosporin you should avoid potassium-containing salt substitutes or over-the-counter potassium supplements without first talking to your doctor. Taking voclosporin together with these salt substitutes or supplements may cause high levels of potassium in your blood. High levels of potassium can cause weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs. Call your doctor at once if you have any of these symptoms. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.